Surgical smoke from robot-assisted radical cystectomy contained no detectable bladder cancer cells, mutations, or exosomes

Port site recurrence and peritoneal dissemination are occasionally observed after robot-assisted radical cystectomy (RARC) for bladder cancer. The investigators hypothesized that surgical smoke produced during RARC might contain viable bladder cancer cells or tumor-derived material capable of seeding these recurrences, and set out to test this across a series of complementary analyses.

The study combined clinical smoke collection during surgery with bench experiments on the T24 bladder cancer cell line. Cytology was first performed on exhaust smoke filters used during laparoscopic radical cystectomy, and no cancer cells were identified. Digital PCR was then applied to surgical smoke captured through a water trap system during RARC, specifically looking for the PIK3CA (E545K) mutation; no mutated gene was detected. T24 cell pellets were subsequently subjected to electrocoagulation vaporization with vacuum capture of the resulting smoke, and digital PCR for the TERT (C228T) mutation was again negative.

In a final step, the authors analyzed exosomes in smoke obtained from electrocoagulated T24 pellets, using the supernatant of T24 cells as the control. Exosome levels in the smoke were significantly lower than those measured in the control supernatant, arguing against meaningful release of tumor-derived vesicles through the electrocoagulation process.

No safety outcomes, adverse events, or patient-level clinical endpoints are reported in the abstract. The abstract does not quantify sample size, exposure durations, or confidence intervals, and limitations are not explicitly described; conclusions rest on negative findings across cytology, targeted mutation assays, and exosome quantification rather than on direct patient follow-up.

For practice, these laboratory-level findings are reassuring but narrow: within the assays used, RARC surgical smoke did not appear to carry bladder cancer cells, the tested driver mutations, or elevated exosomes, though this does not by itself establish the clinical origin of port site or peritoneal recurrences.